Advanced Biologics takes biological innovations to the next level through a merger with Isto Biologics

CARLSBAD, Calif., Oct. 18, 2023 /PRNewswire/ — Advanced Biologics (commercially known as Biologica Technologies), a California-based company known for their innovative biological solutions, today announced their successful merger with Isto Biologics, a global leader in regenerative and autologous therapies.

The merger will seamlessly integrate Advanced Biologics’ proprietary products into Isto’s valued and growing portfolio of allografts within their Influx™ line.

“We are pleased that our entire Advanced Biologics/Biologica team will be joining forces with Isto Biologics,” said Amit Govil, president of Advanced Biologics. “This merger brings together the clinical, commercial and research-driven expertise of both companies and a shared commitment to helping patients heal faster.”

Advanced Biologics has maintained a commercial partnership with Isto Biologics since 2020, catalyzed by the development of Isto’s Integrative Bone Matrix, SPARC^™. SPARC is a novel inductive bone matrix derived from Advanced Biologics’ proprietary tissue processing method used in their signature allograft, OsseoGen®. SPARC is known for its increased levels of osteoinductive, chemotactic, angiogenic and proliferative growth factors.

The integration of Advanced Biologics’ product commercialization initiatives into Isto’s growing allograft portfolio provides a unique opportunity to help patients heal faster and enable both customer bases to benefit from the broader product range.

“Over the past four years, our partnership with Advanced Biologics has been impressive,” said Harry Holiday, Chairman of the Board of Directors of Isto Biologics and Managing Director at Thompson Street Capital Partners (TSCP). “Investing in Advanced Biologics and entering into this strategic combination strengthens the extensive biologics portfolios of both Isto and Advanced Biologics, paving a path forward for continued growth and patient healing.”

“Through this merger, our combined team will now have greater clinical expertise and deeper customer support to provide our champion surgeons with the best products available in the market,” said Don Brown, CEO of Isto Biologics.

About Advanced Biologicals/Biologics Technologies

Advanced Biologics (ABC) is a three-way, Orthopedics this week – Prize for new technology winning biological company focused on developing innovative and clinically relevant biological solutions for a wide range of medical specialties. To better serve customers, Advanced Biologics formed Biologica Technologies in 2015 as a separate, standalone company that will serve as its sales, marketing and clinical research group. Advanced Biologics’ core technology provides the ability to access intracellular growth factors (GFs) found in allograft tissue. ProteiOS® Growth Factor and OsseoGEN® Cellular Bone Matrix are among the first products based on the technology and possess the highest concentration of GFs within their respective biological categories. The company is privately held and headquartered in Carlsbad, CA.

About Isto Biologics

Isto Biologics is a leading biologics and cellular therapy company in the orthopedic sector. Isto Biologics focuses on helping patients heal faster through innovative bone regeneration solutions and cell-based therapies. The company’s flagship product offerings include the market-leading Magellan® Autologous Platelet Separator and bone growth products, including InQu® Bone Graft Extender & Substitute, and the Influx™ product family.

For more information, visit istobiologics.com

SOURCE Advanced Biologicals